Patents Examined by Robert W. Ramsuer
  • Patent number: 6900215
    Abstract: A class of 3-phenylimidazo[1,2-?]pyrimidine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group which is directly attached or bridged by an oxygen atom or a —NH— linkage, and further substituted on the phenyl ring by alkyl, trifluoromethyl, alkoxy or one or two halogen atoms, especially fluoro, are selective ligands for GABAA receptors, in particular having good affinity for the ?2 and/or ?3 and/or ?5 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.
    Type: Grant
    Filed: March 19, 2002
    Date of Patent: May 31, 2005
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Mark Stuart Chambers, Simon Charles Goodacre, David James Hallett, Andrew Jennings, Philip Jones, Richard Thomas Lewis, Kevin William Moore, Michael Geoffrey Neil Russell, Leslie Joseph Street, Helen Jane Szekeres
  • Patent number: 6869951
    Abstract: The present invention provides a matrix metalloproteinase inhibiting compound having structure (VIII) or a salt, an enantiomer, a diastereomer, a racemate, or a tautomer thereof. In other embodiments, the present invention provides a method of changing the conformation of a matrix metalloproteinase, a method of inhibiting a matrix metal metalloproteinase, and a method of treating osteoarthritis.
    Type: Grant
    Filed: July 12, 2000
    Date of Patent: March 22, 2005
    Assignee: Pharmacia Corporation
    Inventors: William C. Stallings, Huey S. Shieh, Susan C. Howard, Gary A. DeCrescenzo, Joseph J. McDonald
  • Patent number: 6852749
    Abstract: The invention provides the use of an optionally hydroxy-protected 4-hydroxyo or hydroperoxy-3,5-dioxopyrazolidine or an equivalent wherein a pyrazolidine ring attached oxygen is replaced by a sulphur, or a physiologically acceptable salt thereof, for the manufacture of a medicament for use in therapy or prophylaxis. Additionally, the invention provides a method of combating HIV infection which comprises administering to an HIV-infected patient a T-lymphocyte growth suppressing agent, preferably a pyrazolidinol, in an amount sufficient to suppress T-lymphocyte growth in said patient for a period sufficient to reduce the T-lymphocyte concentration in lymph nodes in said patient by at least 25%, said administration being repeated at intervals of at least 3 months.
    Type: Grant
    Filed: June 29, 2000
    Date of Patent: February 8, 2005
    Inventors: Enok Tjøtta, Jo Klaveness
  • Patent number: 6831082
    Abstract: Disclosed are novel compounds of the formula Ia and methods of using soluble epoxide hydrolase (sEH) inhibitors of the formulas I and Ia for diseases related to cardiovascular disease.
    Type: Grant
    Filed: June 14, 2002
    Date of Patent: December 14, 2004
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Richard H. Ingraham, John R. Proudfoot
  • Patent number: 6825222
    Abstract: The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof: In Structural Formula I, n is 2, 3, or 4; V is O or S; W is O, S, or SO2; R1 is H, a C1-C4 alkyl, phenyl or trifluoromethyl; R2 are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, a cycloalkyl, or together with the phenyl to which they are bound form naphthyl or 1,2,3,4-tetrahydronaphthyl; R3 are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, or a cycloalkyl; R4 are each, independently, H, a C1-C4 alkyl, an aryl, or benzyl; R5 are each, independently, H, a substituted or unsubstituted aryl or a heteroaryl, provided that at least one R5 is a substituted or u
    Type: Grant
    Filed: May 7, 2003
    Date of Patent: November 30, 2004
    Assignees: Eli Lilly and Company, Ligand Pharmaceuticals, Inc.
    Inventors: Dawn A. Brooks, Christopher J. Rito, Anthony J. Shuker, Samuel J. Dominianni, Alan M. Warshawsky, Lynn S. Gossett, Donald P. Matthews, David A. Hay, Robert J. Ardecky, Pierre-Yves Michellys, John S. Tyhonas
  • Patent number: 6800659
    Abstract: Novel styrylacrylonitrile compounds which are useful in treating a variety of cell proliferative disorders such as cancer are disclosed.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: October 5, 2004
    Assignee: HSC Research and Development Limited Partnership
    Inventors: Chaim M. Roifman, Thomas Grunberger, Olga Rounova, Demin Peter, Nigel Sharfe
  • Patent number: 6790975
    Abstract: This invention is an aminostyrylanthracene compound represented by, for example, the following general formula [I]. This compound is produced by condensation from a corresponding aminobenzaldehyde and a phosphonic ester or phosphonium salt. [where, in the general formula [I] above, R2 represents an unsubstituted aryl group, R1 represents an aryl group which may have a variety of substituents, and R3 to R5 each represent a hydrogen atom, a cyano group, or a hydrocarbon group.
    Type: Grant
    Filed: March 19, 2002
    Date of Patent: September 14, 2004
    Assignee: Sony Corporation
    Inventors: Mari Ichimura, Tadashi Ishibashi, Shinichiro Tamura
  • Patent number: 6787543
    Abstract: A compound of the formula (I): in which Z, R1, R2, R8, R10, R11, R12, R13 and R14 are each as defined in the description, or a salt thereof. The object compound of the present invention has pharmacological activities such as Tachykinin antagonism, and is useful for manufacture of a medicament for treating or preventing Tachykinin-mediated diseases.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: September 7, 2004
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Kazuhiko Take, Chiyoshi Kasahara, Shinji Shigenaga, Hidenori Azami, Yoshiteru Eikyu, Kazuo Nakai, Masataka Morita
  • Patent number: 6770599
    Abstract: The instant invention relates to novel tetrazole derivatives of the formula (I) wherein R1 represents halogen, methyl, ethyl, halomethyl, methoxy, ethoxy, C1-2 haloalkoxy, methylthio, ethylthio, C1-3 alkylsulfonyl, methylsulfonyloxy, ethylsulfonyloxy, nitro or cyano, R2 represents C1-6 alkyl, C3-6 cycloalkyl which may be optionally substituted with halogen or C1-3 alkyl, C1-4 haloalkyl, C2-6 alkenyl, or phenyl which may be optionally substituted with halogen, C1-3 alkyl, C1-4 haloalkyl, C2-6 alkenyl, or phenyl which may be optionally substituted with halogen, C1-3 alkyl, C1-2 haloalkyl or nitro, m represents 0, 1 or 2, two R1 s may be identical or different, in case m represents 2, n represents 1 or 2, Q represents one the cyclic groups which are mentioned in the specification, to intermediates and several processes for their preparation, to their use as herbicides and to novel compositions containing them.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: August 3, 2004
    Assignee: Bayer CropScience KK
    Inventors: Akihiko Yanagi, Shinichi Narabu, Toshio Goto, Chieko Ueno, Shinichi Shirakura
  • Patent number: 6762306
    Abstract: There is disclosed a chiral phosphine compound of formula (1): wherein R1, R2, and Ar are as defined in the specification. The chiral phosphine compound is suitably used to produce a transition metal complex that is useful as an asymmetric reaction catalyst.
    Type: Grant
    Filed: March 14, 2002
    Date of Patent: July 13, 2004
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Heikki Hassila, Takayuki Higashii
  • Patent number: 6756394
    Abstract: The invention features methods for decreasing necrosis. The invention also features methods for treating a subject with a condition in which necrosis occurs. The invention further features chemical compounds used to decrease necrosis.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: June 29, 2004
    Assignee: President and Fellow of Harvard College
    Inventors: Junying Yuan, Alexei Degterev, Timothy J. Mitchison
  • Patent number: 6756385
    Abstract: The invention provides compounds of formula 1 wherein R1, R2, R3, and R4 are as defined, and their pharmaceutically acceptable salts. Compounds of formula 1 are indicated to have activity inhibiting cdk5, cdk2, and GSK-3. Pharmaceutical compositions and methods comprising compounds of formula 1 for treating and preventing diseases and conditions comprising abnormal cell growth, such as cancer, and neurodegenerative diseases and conditions and those affected by dopamine neurotransmission.
    Type: Grant
    Filed: July 31, 2001
    Date of Patent: June 29, 2004
    Assignee: Pfizer Inc.
    Inventors: Mark A. Sanner, Chris J. Helal, Christoper B. Cooper, Frank S. Menniti, Michael K. Ahlijanian, Annabella Villalobos, Lit-Fui Lau, Patricia A. Seymour
  • Patent number: 6756375
    Abstract: The invention provides for a non-steroidal compound having the formula wherein Re and ′Re are OH, optionally independently etherified or esterified; Z is —CH2— or —CH2CH2—; R1 is H, halogen, CF3, or (1C-4C)alkyl; R2, R3 and R4 are independently H, halogen, —CF3, —OCF3, (1C-8C)Alkyl, hydroxy, (1C-8C)alkyloxy, aryloxy, aryl(1C-8C)alkyl, halo(1C-8C)alkyl, —O(CH2)mX, wherein X is halogen or phenyl and m=2-4; —O(CH2)mNRaRb, —S(CH2)mNRaRb or —(CH2)mNRaRb, wherein m=2-4 and Ra, Rb are independently (1C-8C)alkyl, (2C-8C)alkenyl, (2C-8C)alkynyl, or aryl, optionally substituted with halogen, —CF3, —OCF3, —CN, —NO2, —OH, (1C-8C)alkoxy, aryloxy, carboxyl, (1C-8C)alkylthio, carboxylate, (1C-8C)alkyl, aryl, aryl(1C-8C)alkyl, halo(1C-8C)alkyl or Ra and Rb form a 3-8 membered ring structure, optionally substituted with halogen, —CF3, —OCF3, —CN, —NO2, hydroxy, hydroxy(1C-4C)a
    Type: Grant
    Filed: July 24, 2003
    Date of Patent: June 29, 2004
    Assignee: Akzo Nobel N.V.
    Inventors: Gerrit Herman Veeneman, Hubert JanJozef Loozen, Jordi Mestres, Eduard Willem De Zwart
  • Patent number: 6756372
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: June 29, 2004
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Michel Jose Emmanuel, Weimin Liu, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey David Ward
  • Patent number: 6753329
    Abstract: The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.
    Type: Grant
    Filed: December 17, 2002
    Date of Patent: June 22, 2004
    Assignees: GPC Biotech Inc., GPC Biotech AG
    Inventors: Nicholas Bockovich, Arthur Kluge, Chris Oalmann, Krishna K. Murthi, Frank Becker
  • Patent number: 6750352
    Abstract: A polymerizable molten salt monomer represented by the following general formula (I): wherein Q represents a nitrogen-containing aromatic heterocyclic atomic group which can form a cation; Y1 represents a divalent interlocking group or a bonding hand; Y2 represents a substituted or unsubstituted alkyl group; n represents an integer of from 2 to 20; m represents an integer of 2 or more; X− represents an anion; plural Y1's and plural Y2's may be the same or different, respectively, with the proviso that at least one of Y2's has a polymerizable substituent group; and a plurality of the compounds of the general formula (I) may be connected to each other at Q or Y2 to form a dimer, trimer or tetramer. Also disclosed are an electrolyte composition containing a polymer compound obtained by the polymerization of the molten salt monomer, and a cell containing the electrolyte composition.
    Type: Grant
    Filed: January 22, 2001
    Date of Patent: June 15, 2004
    Assignee: Fuji Photo Film Co., Ltd.
    Inventors: Michio Ono, Chang-yi Qian
  • Patent number: 6750338
    Abstract: This invention relates to a novel process of preparing selected 5-substituted pyrazoles useful as p38 kinase and COX-2 inhibitors.
    Type: Grant
    Filed: October 10, 2002
    Date of Patent: June 15, 2004
    Assignee: Pharmacia Corporation
    Inventors: Matthew J. Graneto, Michael L. Vazquez, Susan J. Hartmann, Suzanne Metz, John J. Talley, David L. Brown, Richard M. Weier, Michael A. Stealey, Xiangdong Xu
  • Patent number: 6747049
    Abstract: Compounds of formula I are provided as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R3 and n have the significance given in the specification can be used to treat non-insulin dependent diabetes mellitus.
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: June 8, 2004
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Brodbeck, Hans Hilpert, Roland Humm
  • Patent number: 6747150
    Abstract: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.
    Type: Grant
    Filed: March 19, 2003
    Date of Patent: June 8, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Julian Adams, Yu-Ting Ma, Ross Stein, Matthew Baevsky, Louis Grenier, Louis Plamondon
  • Patent number: 6740684
    Abstract: A strong-acid cation exchange resin in acid form is contacted with an alkylcarhamoyl alkylthioester in the presence of water for producing a strong-acid cation exchange resin comprising a plurality of acid groups being partially neutralized with a mercaptoalkylamine. The produced partially neutralized cation exchange resin is useful as a catalyst in a process of producing a bisphienol by reaction of a phenolic compound with a carhonyl compound.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: May 25, 2004
    Assignee: Dow Global Technologies Inc.
    Inventors: Mihail Paliuras, Damian M. Feord, Johann-Wilhelm Frey